

PATIENTS ADVICE

Before and after a treatment, we recommend:

For **STYLAGE® S, STYLAGE® M, STYLAGE® L, STYLAGE® Special Lips (with and without Lidocaïne) and STYLAGE® Lips Plus** treatments:

- Use a sunscreen with a high protection factor during the two weeks following treatment.
- Do not wear make-up during the 12 hours following the injection and avoid exposing the treated area to intense heat (UV, sauna, steam room) or extreme cold, at least until any potential post-injection swelling or redness disappear.
- The patient must keep informed the practitioner of any "abnormal" developments in the treated area (see adverse effects).

For **STYLAGE® XL (with and without Lidocaïne) and STYLAGE® XXL** treatments:

- Use a sunscreen with a high protection factor during the two weeks following treatment.
- Do not wear make-up during the 12 hours following the injection and avoid exposing the treated area to intense heat (UV, sauna, steam room) or extreme cold, at least until any potential post-injection swelling or redness disappear.
- The patient must keep informed the practitioner of any "abnormal" developments in the treated area (see adverse effects).
- Avoid any massage or compression of the injected area for the first 3 days after the injection.
- Avoid the sauna, steam room, and vigorous sports during the first week after injection.

For **STYLAGE® Hydro et STYLAGE® HydroMax** treatments:

- Thoroughly massage yourself in the days after the injection, particularly when the micropapular technique is used.
- Use a sunscreen with a high protection factor during the two weeks following treatment.
- Do not wear make-up during the 12 hours following the injection and avoid exposing the treated area to intense heat (UV, sauna, steam room) or extreme cold, at least until any potential post-injection swelling or redness disappear.
- The patient must keep informed the practitioner of any "abnormal" developments in the treated area (see adverse effects).

For **Desirial®** treatments:

- Avoid taking aspirin, NSAIDs, platelet aggregation inhibiting drugs, anticoagulants or Vitamin C in the week preceding the injection.
- Slight bleeding may be observed after the injection.
- Notify your doctor if you are undergoing treatment with anticoagulants or if you are suffering from a haemostatic disorder (increased risk of haematomas).
- After the injection, avoid going to wet locations (swimming pools, gyms, steam rooms, jacuzzis, etc.) for 10 days.
- Avoid any sexual activity for 5 days.

- Avoid any activities that put pressure on the treated area (cycling, horseback riding, etc.) for several days.

For Desirial® Plus treatments:

- Avoid taking aspirin, NSAIDs, platelet aggregation inhibiting drugs, anticoagulants or Vitamin C in the week preceding the injection.
- Slight bleeding may be observed after the injection.
- Notify your doctor if you are undergoing treatment with anticoagulants or if you are suffering from a haemostatic disorder (increased risk of haematomas).
- After the injection, avoid going to wet locations (swimming pools, gyms, steam rooms, jacuzzis, etc.) for 10 days.
- Avoid any sexual activity for 5 days.
- Avoid any activities that put pressure on the treated area (cycling, horseback riding, etc.) for several days.

For Kartilage®, Kartilage® Cross, HappyCross, HappyMini et HappyVisc treatments:

- Avoid strenuous activity or prolonged weight-bearing activities such as tennis, running or long walks within 48 hours following the injection.
- The patient must keep the practitioner informed of any “abnormal” developments in the treated area (see adverse effects).
- Use an ice-pack post-injection particularly if there is pain or oedema.

ADVERSE EFFECTS

Immediate or delayed adverse effects may occur following injection of the products, in particular (this list is not exhaustive).

For STYLAGE® S, STYLAGE® M, STYLAGE® L, STYLAGE® Special Lips (with and without Lidocaine) and STYLAGE® Lips Plus treatments:

- Inflammatory reactions such as redness, oedema, or erythema, potentially associated with itching and/or pain at the injection site, which usually resolve in less than a week.
- Haematomas.
- Induration or nodules, colouration or discolouration in the injected area.
- Poor efficacy or a weak filling effect.
- Local mobility of the implant.
- Rare cases of necrosis, abscesses, granulomas and hypersensitivity have been reported in literature following injections of hyaluronic acid. The patient must be informed about this.
- In patients who have a severe predisposition to allergies, dermatological disease, haemostasis disorder, or inflammatory disease, or in the event the precautions for use have not been observed, the incidence of adverse effects may increase.
- The patient must inform the practitioner of any adverse effects mentioned above that lasts for more than one week, or the appearance of any other adverse effect. The practitioner must report it to the reseller or manufacturer as soon as possible and should carry out an appropriate care.

For STYLAGE® XL (with and without Lidocaine) and STYLAGE® XXL treatments:

- Inflammatory reactions such as redness, oedema, or erythema, potentially associated with itching
- and/or pain at the injection site, which usually resolve in less than a week.
- Haematomas.
- Induration or nodules, colouration or discolouration in the injected area.
- Poor efficacy or a weak filling effect.
- Local mobility of the implant.
- Rare cases of necrosis, abscesses, granuloma and hypersensitivity have been reported in literature following injections of hyaluronic acid. The patient must be informed about this.
- In patients who have a severe predisposition to allergies, dermatological disease, haemostasis disorder, or inflammatory disease, or in the event the precautions for use have not been observed, the incidence of adverse effects may increase.
- The patient must inform the practitioner of any adverse effects mentioned above that lasts for more than one week, or the appearance of any other adverse effect. The practitioner must report it to the reseller or manufacturer as soon as possible and should carry out an appropriate care.

For STYLAGE® Hydro et STYLAGE® HydroMax treatments:

- Inflammatory reactions such as redness, oedema or erythema, potentially associated with itching and/or pain at the injection site, which usually resolve in less than a week.
- Haematomas.

- Induration or nodules, colouration or discolouration in the injected area.
- Poor efficacy or a weak filling effect.
- Local mobility of the implant.
- Rare cases of necrosis, abscesses, granulomas and hypersensitivity have been reported in literature following injections of hyaluronic acid. The patient must be informed about this.
- In patients who have a severe predisposition to allergies, dermatological disease, haemostasis disorder, or inflammatory disease, or in the event the precautions for use have not been observed, the incidence of adverse effects may increase.
- The patient must inform the practitioner of any adverse effects mentioned above that lasts for more than one week, or the appearance of any other adverse effect.
- The practitioner must report it to the reseller or manufacturer as soon as possible and should carry out an appropriate care.

For Desirial® treatments:

- Inflammatory reactions such as redness, oedema or erythema that may be combined with itching and/or pain at the injection site and which generally disappear after a few days.
- Induration(s) or nodules, colouration or discolouration in the injected area.
- Slight bleeding at the injection site.
- Post-injection pain.
- Haematomas.
- Difficulties urinating.
- Rare cases of necrosis, abscess, granulomas and hypersensitivity after injections of hyaluronic acid into the face have been described in the literature. The patient must be informed of this.
- In patients with a severe predisposition to allergies, dermatological disease, problems with haemostasis or inflammatory disease or if the precautions for use are not adhered to, the incidence of adverse events may be increased.
- Any of the aforementioned side effects that persist for more than a week or the appearance of any other adverse effect must be notified to the doctor by the patient. The doctor must remedy this using an appropriate treatment and notify the distributor or the manufacturer about the problem as soon as possible.

For Desirial® Plus treatments:

- Inflammatory reactions such as redness, oedema or erythema that may be combined with itching and/or pain at the injection site and which generally disappear after a few days.
- Induration(s) or nodules, colouration or discolouration in the injected area.
- Slight bleeding at the injection site.
- Post-injection pain.
- Local mobility of the implant
- Haematomas.
- Rare cases of necrosis, abscess, granulomas and hypersensitivity after injections of hyaluronic acid into the face have been described in the literature. The patient must be informed of this.
- In patients with a severe predisposition to allergies, dermatological disease, problems with haemostasis or inflammatory disease or if the precautions for use are not adhered to, the incidence of adverse events may be increased.
- Any of the aforementioned side effects that persist for more than a week or the appearance of any other adverse effect must be notified to the doctor by the patient. The doctor must

remedy this using an appropriate treatment and notify the distributor or the manufacturer about the problem as soon as possible.

For Kartilage[®], Kartilage[®] Cross, HappyCross, HappyMini et HappyVisc treatments:

- Arthralgia, discomfort, joint stiffness, joint effusion.
- Musculoskeletal disorders.
- Sensation of warmth, feeling of heaviness.
- Skin and subcutaneous tissue disorders (erythema, pruritus).
- Haematomas.

The above-mentioned adverse effects should not last more than a week and can be alleviated by the application of ice post-injection.

- Poor efficacy or weak effect.
- Rarely, post-operative complications may appear such as infection, bleeding, septic arthritis.
- Rare cases of hypersensitivity have been reported in literature following injections of hyaluronic acid. The patient must be informed about this.
- In patient who have a severe predisposition to allergies, dermatological disease, haemostasis disorder, or inflammatory disease, or in the event the precautions for use have not been observed, the incidence of adverse effects may increase.
- The patient must inform the practitioner of any adverse effects mentioned above that lasts for more than one week, or the appearance of any other adverse effect. The practitioner must report it to the reseller or manufacturer as soon as possible and should carry out an appropriate care.

For I-Space, ViscoSert, CistaVisc treatments:

Post-operative transient increase in intraocular pressure if the OVD is not removed as completely as possible. A careful monitoring must be set up to manage any increased post-operative intraocular pressure and to reduce the likelihood of occurrence of secondary glaucoma or other ocular damage.

- Rarely post-operative inflammatory reactions such as toxic anterior segment syndrome (TASS), endophthalmitis, as well as corneal oedema have been reported in literature following injections of sodium hyaluronate. Nevertheless, no relationship with the product has been established.
- Rare cases of hypersensitivity have been reported in literature following injections of sodium hyaluronate. The patient must be informed about this.
- The patient must inform the practitioner of any adverse effects mentioned above, or the appearance of any other adverse effect. The practitioner must report it to the reseller or manufacturer as soon as possible and should carry out an appropriate care.